William Blair Forecasts Pyxis Oncology Q1 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Stock analysts at William Blair issued their Q1 2026 earnings estimates for shares of Pyxis Oncology in a research note issued on Friday, August 15th. William Blair analyst A. Hsieh anticipates that the company will earn ($0.36) per share for the quarter. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology’s Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.35) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research note on Monday, May 19th.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $1.23 on Monday. The company has a 50 day moving average price of $1.16 and a 200-day moving average price of $1.15. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.39. The company has a market capitalization of $76.20 million, a PE ratio of -0.77 and a beta of 1.13.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. The firm had revenue of $2.82 million during the quarter.

Institutional Trading of Pyxis Oncology

Several institutional investors and hedge funds have recently modified their holdings of PYXS. Millennium Management LLC increased its holdings in Pyxis Oncology by 53.8% during the fourth quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock valued at $4,650,000 after buying an additional 1,043,228 shares during the period. Jane Street Group LLC increased its holdings in Pyxis Oncology by 36.6% during the fourth quarter. Jane Street Group LLC now owns 67,686 shares of the company’s stock valued at $106,000 after buying an additional 18,128 shares during the period. ProShare Advisors LLC purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $26,000. Ameriprise Financial Inc. purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $35,000. Finally, Caption Management LLC purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $35,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.